首页|辛伐他汀对帕金森病大鼠神经功能的影响

辛伐他汀对帕金森病大鼠神经功能的影响

扫码查看
目的 探究辛伐他汀介导腺苷酸活化蛋白激酶/过氧化物酶体增殖物激活受体γ共激活因子-1α(AMPK/PGC-1α)通路对帕金森病大鼠模型神经功能的影响.方法 SD大鼠建立帕金森病大鼠模型,建模成功后分为模型组、阳性药物组(1.67 mg·kg-1多巴丝肼)、低剂量实验组(10 mg·kg-1辛伐他汀)、高剂量实验组(20 mg·kg-1辛伐他汀)、抑制药组(20 mg·kg-1辛伐他汀+0.25 mg.kg-1的AMPK抑制药BML-275),并选择10只正常大鼠作为对照组.用酶联免疫吸附(ELISA)法检测多巴胺(DA)、3,4二羟基苯乙酸(DOPAC)、高香草酸(HVA)、5羟基吲哚乙酸(5-HIAA)、5羟色胺(5-HT)水平,用蛋白质印迹法检测酪氨酸羟化酶(TH)、AMPK/PGC-1α通路相关蛋白表达水平,用免疫组化法检测TH表达水平,用试剂盒检测丙二醛(MDA)、超氧化物歧化酶(SOD)、谷胱甘肽过氧化物酶(GSH-Px)水平.结果 对照组、模型组、高剂量实验组、抑制药组 DA 分别为(495.63±34.30)、(207.53±24.10)、(429.39±44.89)和(285.55±20.79)pg·mL-1,DOPAC 分别为(33.38±2.48)、(17.70±1.31)、(29.12±1.72)和(20.67±1.45)ng·mL-1,HVA 分别为(58.75±6.25)、(25.27±2.00)、(46.16±2.83)和(30.58±1.91)ng·mL-1,5-HT 分别为(5.62±0.45)、(2.37±0.13)、(4.42±0.26)和(3.23±0.29)ng·mL-1,5-HIAA分别为(11.11±1.08)、(3.88±0.30)、(7.99±0.63)和(6.04±0.51)ng·mL-1,p-AMPK 蛋白表达水平分别为 0.98±0.06、0.35±0.04、0.80±0.05和 0.21±0.02,PGC-1α 蛋白表达水平分别为 1.12±0.11、0.40±0.04、0.90±0.08和0.58±0.05.对照组上述指标与模型组比较、模型组上述指标与高剂量实验组、抑制药组比较,在统计学上差异均有统计学意义(均P<0.05).结论 辛伐他汀可通过调节AMPK/PGC-1α通路改善帕金森病大鼠模型神经功能.
Effect of simvastatin on neural function in rat model of Parkinson's disease
Objective To investigate the effects of simvastatin mediated adenylate activated protein kinase/peroxisome proliferator-activated receptor-γ-coactivator 1 α(AMPK/PGC-1α)pathway on neural function in rats with Parkinson's disease.Methods Parkinson's disease model was established in SD rats.After successful modeling,they were divided into model group,positive group(1.67 mg·kg-1 metoba),experimental-L group(10 mg·kg-1 simvastatin),experimental-H group(20 mg·kg-1 simvastatin),BML-275 group(20 mg·kg-1 simvastatin+0.25 mg·kg-1 AMPK inhibitor BML-275)and 10 normal rats were selected as control group.Enzyme-linked immunosorbent assay(ELISA)was used to detect dopamine(DA),3,4 dihydroxyphenylacetic acid(DOPAC),homovanillic acid(HVA),5-hydroxyindoleacetic acid(5-HIAA),5-hydroxytryptamine(5-HT);Western blot was used to detect the expression of tyrosine hydroxylase(TH)and AMPK/PGC-1α pathway-related proteins;TH expression was detected by immunohistochemistry,malondialdehyde(MDA),superoxide dismutase(SOD)and glutathione peroxidase(GSH-Px)were detected by kit.Results The DA of control group,model group,experimental-H group and BML-275 group were(495.63±34.30),(207.53±24.10),(429.39±44.89)and(285.55±20.79)pg·mL-1,respectively;DOPAC were(33.38±2.48),(17.70±1.31),(29.12±1.72)and(20.67±1.45)ng·mL-1,respectively;HVA were(58.75±6.25),(25.27±2.00),(46.16±2.83)and(30.58±1.91)ng·mL-1,respectively;5-HT were(5.62±0.45),(2.37±0.13),(4.42±0.26)and(3.23±0.29)ng·mL-1,respectively;5-HIAA were(11.11±1.08),(3.88±0.30),(7.99±0.63)and(6.04±0.51)ng·mL-1,respectively;p-AMPK protein expression were 0.98±0.06,0.35±0.04,0.80±0.05 and 0.21±0.02,respectively;PGC-1α protein expression were 1.12±0.11,0.40±0.04,0.90±0.08 and 0.58±0.05,respectively.There were statistically significant differences in the above indexes between control group and model group,and between model group and experimental-H group and inhibitor group(all P<0.05).Conclusion Simvastatin can improve the neural function of Parkinson's disease rats by regulating AMPK/PGC-1α pathway.

simvastatinadenylate activated protein kinase/peroxlsome proliferator-activated receptor-γ coactivator-1 α pathwayParkinson's diseaseneural function

吕金凤、史艳霞、林艳、韩博

展开 >

张家口学院护理学院,河北张家口 175000

张家口学院医学院,河北张家口 175000

辛伐他汀 腺苷酸活化蛋白激酶/过氧化物酶体增殖物激活受体γ共激活因子-1α通路 帕金森病 神经功能

2024

中国临床药理学杂志
中国药学会

中国临床药理学杂志

CSTPCD北大核心
影响因子:1.91
ISSN:1001-6821
年,卷(期):2024.40(4)
  • 12